Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.67 |
| ▸ | TGFB2 | P61812 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2011307 | 0.80 | TGFBR1 (1.00) | TGFBR1TGFB2MAPK14 | |
| SCHEMBL31498977 | 0.80 | TGFBR1 (1.00) | TGFBR1TGFB2MAPK14 | |
| SCHEMBL2007716 | 0.78 | TGFBR1 (1.00) | TGFBR1TGFB2MAPK14 | |
| SCHEMBL14996211 | 0.78 | TGFBR1 (0.68) | TGFBR1TGFB2MAPK14 | |
| SCHEMBL2008286 | 0.78 | TGFBR1 (1.00) | TGFBR1TGFB2MAPK14 | |
| SCHEMBL31498978 | 0.78 | TGFBR1 (1.00) | TGFBR1TGFB2MAPK14 | |
| SCHEMBL16821958 | 0.77 | TGFBR1 (0.64) | TGFBR1TGFB2MAPK14 | |
| SCHEMBL2011347 | 0.77 | TGFBR1 (1.00) | TGFBR1TGFB2MAPK14 | |
| SCHEMBL29978020 | 0.77 | TGFBR1 (1.00) | TGFBR1TGFB2MAPK14 | |
| SCHEMBL2015728 | 0.76 | TGFBR1 (1.00) | TGFBR1TGFB2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938289-B2 | Therapeutic pyrazolyl thienopyridines | FBM THERAPEUTICS, LLC (US) | 2018-04-10 | — | — | US | disclosed |
| US-20160200735-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | THIRONA BIO, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9260450-B2 | Therapeutic pyrazolyl thienopyridines | THESAN PHARMACEUTICALS, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2527345-B1 | Therapeutic pyrazolyl thienopyridines | THESAN PHARMACEUTICALS INC (US) | 2015-12-16 | — | — | EP | disclosed |
| US-9090625-B2 | Therapeutic pyrazolyl thienopyridines | THESAN PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150175624-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | THIRONA BIO, INC. | 2015-06-25 | — | — | US | disclosed |
| US-20140031385-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | Medicis Phamaceutical Corporation (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2074128-B1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | MEDICIS PHARMACEUTICAL CORP (US) | 2013-08-14 | — | — | EP | disclosed |
| US-8455512-B2 | Therapeutic pyrazolyl thienopyridines | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110224251-A1 | Therapeutic Pyrazolyl Thienopyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2011-09-15 | — | — | US | disclosed |
| US-7964612-B2 | Therapeutic pyrazolyl thienopyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-20080090861-A1 | Cancer and fibrotic disorders such as scarring prevention; 2-(4-methyl-1-(6-methylpyridin-2-yl)-1H-pyrazol-5-yl)thieno[2,3-c]pyridine for example; activin receptor-like kinase-5 (ALK-5) inhibitors | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031385-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885TGFB2 7/4885MAPK14 2610/4885 |
| US-20160200735-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885TGFB2 7/4885MAPK14 2610/4885 |
| US-20110224251-A1 | Therapeutic Pyrazolyl Thienopyridines | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885TGFB2 7/4885MAPK14 2610/4885 |
| US-20150175624-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885TGFB2 7/4885MAPK14 2610/4885 |
| US-20080090861-A1 | Cancer and fibrotic disorders such as scarring prevention; 2-(4-methyl-1-(6-methylpyridin-2-yl)-1H-pyrazol-5-yl)thieno[2,3-c]pyridine for example; activin receptor-like kinase-5 (ALK-5) inhibitors | ACVR1, TGFBR1, ACVRL1 | TGFBR1 2/4885TGFB2 23/4885MAPK14 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.